Sepsis- Pipeline Insight, 2025

This “Sepsis- Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Sepsis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Sepsis: Understanding

Sepsis: Overview

Sepsis is a life-threatening organ dysfunction caused by dysregulated host response to infection. Sepsis is sometimes called septicemia or blood poisoning. If not recognized early, it can lead to septic shock, multiple organ failure and death. It is most frequently a serious complication of infection, particularly in low- and middle-income countries where it represents a major cause of maternal and neonatal morbidity and mortality. Sepsis develops when the immune system releases the chemicals in the bloodstream to fight an infection cause inflammation throughout the entire body instead.

Sepsis cannot spread to other people. Sepsis can be a result of an infection, and some infections can be spread to others. Most sepsis is caused by bacterial infections. It can also be a result of other infections, including viral infections, such as COVID-19 or influenza. An infection of the bone, called osteomyelitis, could lead to sepsis. In people who are hospitalized, bacteria may enter through IV lines, surgical wounds, urinary catheters, and bed sores. Sepsis is more common in people with chronic medical conditions, such as diabetes, lung disease, cancer, and kidney disease, people with weakened immune systems, babies under 1 year of age, elderly people especially if they have other health problems. Most of the time, using a thermometer, it is pretty simple to determine heart rate (counting pulses per minute), fever, or hypothermia, as well as to count breaths per minute even at home. Although it may be more challenging to identify the source of the infection, sepsis is generally simple to detect in people who have symptoms of infection including a productive cough, dysuria, fevers, or a wound filled with pus. Septic shock is the most severe complication of sepsis and carries high mortality.

Symptoms of septic shock are similar to those of severe sepsis, but it also include a significant drop in blood pressure. This drop in blood pressure can lead to heart failure, stroke, and failure of other organs, respiratory failure, and even death. In addition to the three stages of sepsis, several phases are exist within the first stage of sepsis. The late phase of sepsis is dominated by immune suppression, leading to the hypothesis that the immune system changes from hyper-inflammatory to hypo-inflammatory phases during sepsis. Treatment for sepsis is most effective when started early. Health workers watch for concerning signs and use tests to diagnose sepsis. They will then work to find the source of the infection. Early use of antimicrobials to treat bacteria, parasites, fungus or viruses is essential to improve outcomes from sepsis.

Low blood pressure is treated by intravenous fluids and sometimes medicines called vasopressors, which can increase blood pressure. Antibiotic resistance can make treatment more difficult.

'Sepsis- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines. The assessment part of the report embraces, in depth Sepsis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sepsis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D. The therapies under development are focused on novel approaches to treat/improve Sepsis.

Sepsis Emerging Drugs Chapters

This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sepsis Emerging Drugs

Enibarcimab: AdrenoMed AG

Enibarcimab (HAM8101; fomer name: Adrecizumab) a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Enibarcimab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality as regulator of vascular integrity. Enibarcimab targets Adrenomedullin (ADM), a vasoprotective peptide hormone. ADM that remains in the bloodstream, however, has a different effect, one that helps mitigate sepsis: promoting stability of the endothelial barrier by restoring the cell junctions between endothelial cells that ordinarily regulate molecule transport and leakage. In health, levels of ADM in the bloodstream and extravascular space are in equilibrium so that endothelial barrier integrity is maintained and blood pressure remains normal. Currently, the drug is in Phase II stage of its development for the treatment of sepsis.

M 6229: Matisse Pharmaceuticals

Matisse’s platform technology is based on the discovery that in many patients suffering from sepsis, proteins called histones are released by the innate immune system and dying cells into the blood stream, where they are toxic to other cells. Due to a self-enforcing cascade, people may die from organ failure within one or two days. Preclinical results have shown that by neutralizing the toxic histones with Matisse’s product M6229, the negative cascade is terminated by neutralization of cationic histones by anionic M6229. Matisse claims to have identified an elegant solution for treating one of the major complications in sepsis by using a non-anticoagulant fraction of heparin called M6229 to neutralize toxic circulatory histones .Currently, the drug is in Phase II stage of its development for the treatment of sepsis.

SNIPR 001: SNIPR Biome

SNIPR001 is a novel, orally-administered antibiotic that is designed to precisely target difficult-to-treat bacterial infections. It is developed using SNIPR Biome's CRISPR-Guided Vectors™ (CGV™ Technology), which is designed to deliver CRISPR reagents into target bacterial cells. SNIPR001 is designed to target certain E. coli bacteria in the gut and thus prevent their translocation to the bloodstream, without affecting beneficial bacteria in the microbiome. It contains four CRISPR-armed phages that selectively target and eliminate E. coli strains that are resistant to fluoroquinolone, with demonstrated efficacy in animal disease models. Currently, the drug is in preclinical stage of its development for the treatment of sepsis.

Sepsis: Therapeutic Assessment

This segment of the report provides insights about the different Sepsis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Sepsis

• There are approx. 25+ key companies which are developing the therapies for Sepsis. The companies which have their Sepsis drug candidates in the most advanced stage, i.e. phase III include, AdrenoMed AG.

Phases

The report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Sepsis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sepsis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sepsis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.

Sepsis Report Insights

• Sepsis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Sepsis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Sepsis drugs?
• How many Sepsis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sepsis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sepsis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sepsis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AdrenoMed AG
• Matisse Pharmaceuticals
• SNIPR Biome
• Tianjin Chase Sun Pharmaceutical
• Beijing Scitech-Mq Pharmaceuticals
• Recce Pharmaceuticals
• Inotrem
• Octapharma
• Shaperon
• Shionogi
• Pharmazz
• Seres Therapeutics

Key Products

• Enibarcimab
• M 6229
• SNIPR 001
• Kukoamine B
• ST-1830
• RECCE 327
• Nangibotide
• OctaplasLG
• HY209
• Cefiderocol
• Centhaquine
• SER 155

This product will be delivered within 1-3 business days.